Human papillomavirus vaccine timing associated with eventual human papillomavirus diagnosis in women
Document Type
Article
Publication Date
9-1-2020
Abstract
Nearly all cases of cervical cancer are attributable to human papillomavirus (HPV), making it a significant women’s health issue. Though there have been advances in the prevention of HPV via vaccination, significant barriers continue to suppress vaccination rates for girls. Delaying vaccination until after sexual debut increases a woman’s chance of HPV infection, but there has been no quantification of this risk in the literature. The present study sought to address this gap via secondary data analysis with 173 female participants from the 2015–2016 National Health and Nutrition Examination Survey dataset. Results indicate that women in the sample who received the HPV vaccine after their sexual debut were 2.63 times more likely than women who receive the vaccine before their sexual debut to report an HPV diagnosis. These results have clear public and sexual health implications.
Publication Title
International Journal of STD and AIDS
Volume
31
Issue
10
First Page
976
Last Page
981
Digital Object Identifier (DOI)
10.1177/0956462420937168
PubMed ID
32693737
ISSN
09564624
E-ISSN
17581052
Citation Information
Zeglin, R. J., & Fetteroll, J. L. (2020). Human papillomavirus vaccine timing associated with eventual human papillomavirus diagnosis in women. International Journal of STD & AIDS, 31(10), 976–981. https://doi.org/10.1177/0956462420937168